Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GNI Group ( (JP:2160) ) just unveiled an announcement.
GNI Group’s subsidiary, Gyre Pharmaceuticals, has launched Etorel (Nintedanib Esilate Soft Capsules), marking a strategic advancement in the treatment of pulmonary fibrosis. This launch strengthens Gyre Pharmaceuticals’ position as a global leader in this field, addressing significant unmet clinical needs and expanding its market presence.
The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on treatments for pulmonary fibrosis and interstitial lung diseases through its subsidiary, Gyre Pharmaceuticals Co., Ltd.
Average Trading Volume: 2,703,411
Technical Sentiment Signal: Buy
Current Market Cap: Yen208.9B
Learn more about 2160 stock on TipRanks’ Stock Analysis page.